Rana Malek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rana Malek has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Bayan Mesmar
Department of Internal Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, 827 Linden Avenue, Baltimore, MD 21201, United States
2 shared publicationsSilpa Poola-Kella
Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, University of Maryland Medical Center, Baltimore, MD, USA
2 shared publicationsAmal Shibli-Rahhal
Division of Endocrinology, Diabetes and Metabolism, University of Iowa Carver College of Medicine, Iowa City, Iowa
1 shared publicationAndrew Gianoukakis
Division of Endocrinology, The Lundquist Research Institute at Harbor-UCLA Medical Center, Torrance, California; David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California
1 shared publicationAnn J. Miller
1 shared publication- Ann Miller
Department of Medicine, University of Maryland Medical Center, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 31 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5673
The Effect of Telemedicine in Glycemic Control in Adult Patients with Diabetes during the COVID-19 Era—A Systematic Review
Telemedicine can be an effective tool for managing chronic diseases. The disruption in traditional diabetes care resulting from the COVID-19 pandemic led to global interest in telemedicine. With this manuscript, we evaluated the use of telemedicine for the management of diabetes during the pandemic and its impact on glycemic control, focusing on retrospective and prospective studies which included adult, non-pregnant patients with diabetes. We evaluated whether there was an improvement in HbA1c, time in range (TIR), glucose management indicator (GMI), mean glucose values, hypoglycemic episodes, time below range (TBR), or hospitalizations for hypoglycemia/DKA, depending on the available information provided. This review article highlights the benefits of telemedicine during the global state of emergency, which altered the standard of healthcare delivery. Across the studies reported in this review, telemedicine was shown to be an effective tool for the management of diabetes, illustrating its potential to be the new standard of care. Although these improvements may be confounded by potential extraneous factors present during the pandemic, telemedicine was shown to positively impact glycemic control. Overall, this article highlights the benefits of telemedicine on glycemic control during the global state of emergency, which altered the standard of care. With the rollback of COVID-19 restrictions, and a return to the office, this article emphasizes the necessity to study how telemedicine can be best utilized for diabetes management when compared to the traditional standard of care.
- 31 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5673
Open AccessThe Effect of Telemedicine in Glycemic Control in Adult Patients with Diabetes during the COVID-19 Era—A Systematic Review
Telemedicine can be an effective tool for managing chronic diseases. The disruption in traditional diabetes care resulting from the COVID-19 pandemic led to global interest in telemedicine. With this manuscript, we evaluated the use of telemedicine for the management of diabetes during the pandemic and its impact on glycemic control, focusing on retrospective and prospective studies which included adult, non-pregnant patients with diabetes. We evaluated whether there was an improvement in HbA1c, time in range (TIR), glucose management indicator (GMI), mean glucose values, hypoglycemic episodes, time below range (TBR), or hospitalizations for hypoglycemia/DKA, depending on the available information provided. This review article highlights the benefits of telemedicine during the global state of emergency, which altered the standard of healthcare delivery. Across the studies reported in this review, telemedicine was shown to be an effective tool for the management of diabetes, illustrating its potential to be the new standard of care. Although these improvements may be confounded by potential extraneous factors present during the pandemic, telemedicine was shown to positively impact glycemic control. Overall, this article highlights the benefits of telemedicine on glycemic control during the global state of emergency, which altered the standard of care. With the rollback of COVID-19 restrictions, and a return to the office, this article emphasizes the necessity to study how telemedicine can be best utilized for diabetes management when compared to the traditional standard of care.
- 24 June 2023
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 52 (4)
Recognizing and Addressing Health Inequities in Endocrinology and Diabetes
- 24 June 2023
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 52 (4)
Recognizing and Addressing Health Inequities in Endocrinology and Diabetes
- 7 June 2023
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 52 (4) , 677-687
Challenges of Gender-Affirming Care in Incarcerated Transgender People
- 7 June 2023
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 52 (4) , 677-687
Challenges of Gender-Affirming Care in Incarcerated Transgender People
- Open Access
- 12 October 2022
- Published by Springer Nature in Cureus
- Vol. 14 (10) , e30222
Effects of Electroconvulsive Therapy on Glycemic Control in Type 1 Diabetes
Electroconvulsive therapy (ECT) is a treatment modality for refractory depression and other severe psychiatric diseases. Depression is a common comorbid condition of diabetes. Yet, evidence regarding the effect of ECT on glycemic control in patients with diabetes is limited and conflicting, with reports of both exacerbation and amelioration of hyperglycemia. A 52-year-old Caucasian man with a history of type 1 diabetes mellitus (T1DM) was admitted for ECT therapy in the setting of worsening depression refractory to medical treatment. Pre-admission glycemic control was poor. He had significant glycemic variability during his hospitalization with hyper- and hypoglycemia. He required near-daily adjustment of insulin doses and distinct “ECT day” and “non-ECT day” insulin regimens. By the conclusion of his ECT course, in addition to achieving favorable psychiatric recovery, he had a marked improvement in glycemic control. This suggests that the treatment of depression may have beneficial effects on improving glycemic control in patients with T1DM.
- 12 October 2022
- Published by Springer Nature in Cureus
- Vol. 14 (10) , e30222
Open AccessEffects of Electroconvulsive Therapy on Glycemic Control in Type 1 Diabetes
Electroconvulsive therapy (ECT) is a treatment modality for refractory depression and other severe psychiatric diseases. Depression is a common comorbid condition of diabetes. Yet, evidence regarding the effect of ECT on glycemic control in patients with diabetes is limited and conflicting, with reports of both exacerbation and amelioration of hyperglycemia. A 52-year-old Caucasian man with a history of type 1 diabetes mellitus (T1DM) was admitted for ECT therapy in the setting of worsening depression refractory to medical treatment. Pre-admission glycemic control was poor. He had significant glycemic variability during his hospitalization with hyper- and hypoglycemia. He required near-daily adjustment of insulin doses and distinct “ECT day” and “non-ECT day” insulin regimens. By the conclusion of his ECT course, in addition to achieving favorable psychiatric recovery, he had a marked improvement in glycemic control. This suggests that the treatment of depression may have beneficial effects on improving glycemic control in patients with T1DM.
- 17 August 2022
- Published by Elsevier in Endocrine Practice
- Vol. 28 (11) , 1159-1165
An Assessment of Diversity, Inclusion, and Health Equity Training in Endocrinology Fellowship Programs in the United States
- 17 August 2022
- Published by Elsevier in Endocrine Practice
- Vol. 28 (11) , 1159-1165
An Assessment of Diversity, Inclusion, and Health Equity Training in Endocrinology Fellowship Programs in the United States
- 1 December 2021
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 132 (6) , e190-e197
Thyroid carcinoma discovered incidentally during surgical resection of head and neck squamous cell carcinoma: A case series
- 1 December 2021
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 132 (6) , e190-e197
Thyroid carcinoma discovered incidentally during surgical resection of head and neck squamous cell carcinoma: A case series
- 1 August 2021
- Published by Elsevier in Endocrine Practice
- Vol. 27 (8) , 842-849
Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review
- 1 August 2021
- Published by Elsevier in Endocrine Practice
- Vol. 27 (8) , 842-849
Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review
- 2 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8) , e3032-e3033
Letter to the Editor from Malek et al: “Trends in Endocrinology Fellowship Recruitment: Reasons for Concern and Possible Interventions”
Rana Malek, M.D, Elizabeth M Lamos, M.D; Letter to the Editor from Malek et al: Trends in Endocrinology Fellowship Recruitment: Reasons for Concern and Possibl
- 2 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8) , e3032-e3033
Letter to the Editor from Malek et al: “Trends in Endocrinology Fellowship Recruitment: Reasons for Concern and Possible Interventions”
Rana Malek, M.D, Elizabeth M Lamos, M.D; Letter to the Editor from Malek et al: Trends in Endocrinology Fellowship Recruitment: Reasons for Concern and Possibl
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
A rare case of type-2 familial partial lipodystrophy (FLD type 2) non-Dunnigan type with laminin A/C gene (LMNA) mutation causing multi-organ failure and diabetes mellitus
Introduction: Mutations of the LMNA gene cause a wide range of diseases including lipodystrophy, myopathy [including dilated cardiomyopathy (DCM)], neuropathy and progeroid syndrome, and are collectively known as A-type laminopathies. Case report: A 51-year-old Caucasian male with history of heart, liver and kidney transplants was referred for evaluation and treatment of post-transplant diabetes. He was diagnosed with hypertriglyceridemia at age 38. At 43, he was diagnosed with idiopathic cardiomyopathy. Subsequently, he developed liver failure that was presumed to be secondary to passive congestion from heart failure. He underwent simultaneous heart and liver transplants at 44. By age 51, he developed end stage renal disease, treated with hemodialysis prior to recent renal transplant. He developed post-transplant diabetes and endocrine consult was requested. He was noted to be extremely thin with BMI 17.4 kg/m2 (weight=130 lbs, height=6′1″), with generalized lipodystrophy including face, trunk and extremities. Diabetes was managed with a basal/bolus insulin regimen requiring approximately 1.8 units of insulin/kg to control hyperglycemia suggesting severe insulin resistance. Laboratory evaluation was notable for leptin of 2.5 ng/ml (0.3–13.4). Genetic testing revealed a heterozygous LMNA gene missense mutation (c.1045 C>T; p. Arg349Trp). Since identification of the mutation, metformin was added to the insulin with the goal of improving insulin resistance. Discussion: To date, 19 additional patients have been reported with the c.1045C>T LMNA mutation identified in our patient, including a family with 16 affected members, of whom 4 had renal disease. Patients with c.1045C>T mutations have partial lipodystrophy of the non-Dunnigan type (affecting face and extremities), with the exception of one with Dunnigan-type. In the 19 patients, DCM was noted in less than half and elevated creatine kinase, with or without clinical signs of myopathy, was also noted. Less than half had overt diabetes and at least one had euglycemic insulin resistance. The c.1045 C>T variant was not observed in the NHLBI Exome sequencing project, 1000 Genomes Project or Exome Aggregation Consortium database; however the p.Arg349Trp substitution has been identified in patients with skeletal, cardiac and metabolic phenotypes. Collective evidence supports c.1045 C>T as a likely pathogenic variant for an A-type laminopathy and the multiorgan failure seen in our patient. Multiorgan failure should alert endocrinologists of the possibility of LMNA mutation.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
A rare case of type-2 familial partial lipodystrophy (FLD type 2) non-Dunnigan type with laminin A/C gene (LMNA) mutation causing multi-organ failure and diabetes mellitus
Introduction: Mutations of the LMNA gene cause a wide range of diseases including lipodystrophy, myopathy [including dilated cardiomyopathy (DCM)], neuropathy and progeroid syndrome, and are collectively known as A-type laminopathies. Case report: A 51-year-old Caucasian male with history of heart, liver and kidney transplants was referred for evaluation and treatment of post-transplant diabetes. He was diagnosed with hypertriglyceridemia at age 38. At 43, he was diagnosed with idiopathic cardiomyopathy. Subsequently, he developed liver failure that was presumed to be secondary to passive congestion from heart failure. He underwent simultaneous heart and liver transplants at 44. By age 51, he developed end stage renal disease, treated with hemodialysis prior to recent renal transplant. He developed post-transplant diabetes and endocrine consult was requested. He was noted to be extremely thin with BMI 17.4 kg/m2 (weight=130 lbs, height=6′1″), with generalized lipodystrophy including face, trunk and extremities. Diabetes was managed with a basal/bolus insulin regimen requiring approximately 1.8 units of insulin/kg to control hyperglycemia suggesting severe insulin resistance. Laboratory evaluation was notable for leptin of 2.5 ng/ml (0.3–13.4). Genetic testing revealed a heterozygous LMNA gene missense mutation (c.1045 C>T; p. Arg349Trp). Since identification of the mutation, metformin was added to the insulin with the goal of improving insulin resistance. Discussion: To date, 19 additional patients have been reported with the c.1045C>T LMNA mutation identified in our patient, including a family with 16 affected members, of whom 4 had renal disease. Patients with c.1045C>T mutations have partial lipodystrophy of the non-Dunnigan type (affecting face and extremities), with the exception of one with Dunnigan-type. In the 19 patients, DCM was noted in less than half and elevated creatine kinase, with or without clinical signs of myopathy, was also noted. Less than half had overt diabetes and at least one had euglycemic insulin resistance. The c.1045 C>T variant was not observed in the NHLBI Exome sequencing project, 1000 Genomes Project or Exome Aggregation Consortium database; however the p.Arg349Trp substitution has been identified in patients with skeletal, cardiac and metabolic phenotypes. Collective evidence supports c.1045 C>T as a likely pathogenic variant for an A-type laminopathy and the multiorgan failure seen in our patient. Multiorgan failure should alert endocrinologists of the possibility of LMNA mutation.